Literature DB >> 11485986

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.

C Dai1, J C Celestino, Y Okada, D N Louis, G N Fuller, E C Holland.   

Abstract

We present evidence that some low-grade oligodendrogliomas may be comprised of proliferating glial progenitor cells that are blocked in their ability to differentiate, whereas malignant gliomas have additionally acquired other mutations such as disruption of cell cycle arrest pathways by loss of Ink4a-Arf. We have modeled these effects in cell culture and in mice by generating autocrine stimulation of glia through the platelet-derived growth factor receptor (PDGFR). In cell culture, PDGF signaling induces proliferation of glial precursors and blocks their differentiation into oligodendrocytes and astrocytes. In addition, coexpression of PDGF and PDGF receptors has been demonstrated in human gliomas, implying that autocrine stimulation may be involved in glioma formation. In this study, using somatic cell type-specific gene transfer we investigated the functions of PDGF autocrine signaling in gliomagenesis by transferring the overexpression of PDGF-B into either nestin-expressing neural progenitors or glial fibrillary acidic protein (GFAP)-expressing astrocytes both in cell culture and in vivo. In cultured astrocytes, overexpression of PDGF-B caused significant increase in proliferation rate of both astrocytes and neural progenitors. Furthermore, PDGF gene transfer converted cultured astrocytes into cells with morphologic and gene expression characteristics of glial precursors. In vivo, gene transfer of PDGF to neural progenitors induced the formation of oligodendrogliomas in about 60% of mice by 12 wk of age; PDGF transfer to astrocytes induced the formation of either oligodendrogliomas or mixed oligoastrocytomas in about 40% of mice in the same time period. Loss of Ink4a-Arf, a mutation frequently found in high-grade human gliomas, resulted in shortened latency and enhanced malignancy of gliomas. The highest percentage of PDGF-induced malignant gliomas arose from of Ink4a-Arf null progenitor cells. These data suggest that chronic autocrine PDGF signaling can promote a proliferating population of glial precursors and is potentially sufficient to induce gliomagenesis. Loss of Ink4a-Arf is not required for PDGF-induced glioma formation but promotes tumor progression toward a more malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485986      PMCID: PMC312748          DOI: 10.1101/gad.903001

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  60 in total

1.  Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein.

Authors:  P Bertrand; D Rouillard; A Boulet; C Levalois; T Soussi; B S Lopez
Journal:  Oncogene       Date:  1997-03-06       Impact factor: 9.867

2.  Platelet-derived growth factor receptors of mouse central nervous system cells in vitro.

Authors:  J B Hutchins
Journal:  J Comp Neurol       Date:  1995-09-11       Impact factor: 3.215

3.  PDGF mediates a neuron-astrocyte interaction in the developing retina.

Authors:  M Fruttiger; A R Calver; W H Krüger; H S Mudhar; D Michalovich; N Takakura; S Nishikawa; W D Richardson
Journal:  Neuron       Date:  1996-12       Impact factor: 17.173

4.  New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26.

Authors:  D Maier; D Comparone; E Taylor; Z Zhang; O Gratzl; E G Van Meir; R J Scott; A Merlo
Journal:  Oncogene       Date:  1997-08-18       Impact factor: 9.867

5.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene.

Authors:  K Ichimura; E E Schmidt; H M Goike; V P Collins
Journal:  Oncogene       Date:  1996-09-05       Impact factor: 9.867

6.  Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization.

Authors:  R G Weber; M Sabel; J Reifenberger; C Sommer; J Oberstrass; G Reifenberger; M Kiessling; T Cremer
Journal:  Oncogene       Date:  1996-09-05       Impact factor: 9.867

7.  Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor.

Authors:  S C Chua; W K Chung; X S Wu-Peng; Y Zhang; S M Liu; L Tartaglia; R L Leibel
Journal:  Science       Date:  1996-02-16       Impact factor: 47.728

8.  Platelet-derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3-kinase.

Authors:  S Moriya; A Kazlauskas; K Akimoto; S Hirai; K Mizuno; T Takenawa; Y Fukui; Y Watanabe; S Ozaki; S Ohno
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines.

Authors:  M Nistér; T A Libermann; C Betsholtz; M Pettersson; L Claesson-Welsh; C H Heldin; J Schlessinger; B Westermark
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

10.  Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors.

Authors:  A Hall; N A Giese; W D Richardson
Journal:  Development       Date:  1996-12       Impact factor: 6.868

View more
  258 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 4.  Roles of NG2 glial cells in diseases of the central nervous system.

Authors:  Jian-Ping Xu; Jie Zhao; Shao Li
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

Review 5.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

6.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

7.  Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage.

Authors:  Richard A Able; Celestin Ngnabeuye; Cade Beck; Eric C Holland; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2012-06       Impact factor: 2.321

Review 8.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

Review 9.  Stem cells and the origin and propagation of brain tumors.

Authors:  Brian A Emmenegger; Robert J Wechsler-Reya
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

10.  OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.

Authors:  Ying-Wei Lin; Ramona Deveney; Mary Barbara; Norman N Iscove; Stephen D Nimer; Christopher Slape; Peter D Aplan
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.